

References

Books, Articles and Working Papers

- ARROW, Kenneth J.:** *Economic Welfare and the Allocation of Resources for Invention, in The Rate and Direction of Inventive Activity: Economic and Social Factors* 609 (Harold M. Groves ed., 1962).
- BATCHELOR, Bill/ CARLIN, Fiona:** *An Analysis of the European Commission's Pharmaceutical Sector Inquiry* (Pharmaceuticals, Section 3 EU Industry Sectors, The European Antitrust Review 2010, Global Competition Review), available at <http://www.globalcompetitionreview.com/reviews/19/sections/68/chapters/746/pharmaceuticals/>.
- BECHTOLD, Rainer et al.:** *EG Kartellrecht Kommentar Art. 81-86 EG, EG-Kartell-VO 1/2003* (2nd edition, C.H. Beck 2009).
- BERG, Werner/ KÖBELE, Michael:** *Grenzen kartellrechtmäßigen Handelns nach der EU-Untersuchung des Arzneimittelsektors – Risiken und Chancen für betroffene Unternehmen*, 12 PharmR 581 (2009).
- BESEN, Marc et al.:** *Zum Kommissionsbericht über die Untersuchung des Arzneimittelsektors – Kritische Notizen aus patent- und kartellrechtlicher Sicht*, 9 Pharma Recht 432 (2009).
- BHANSALI, Asim:** *Reverse-Payment Settlements After the Federal Circuit's in Re: Ciprofloxacin Decision*, in Patent Law Institute 205 (3rd annual patent law institute 2009).
- BRÜCKNER, Andrea et al.:** *Managing the Profitability of a Mature Product Portfolio: How Intelligent Organizational Approaches, Differentiated Commercial Strategies and Robust Marketing Tactics can drive high-performance in pharmaceutical organizations* (Accenture Management Consulting 2010), available at http://www.accenture.com/Countries/Germany/Research_and_Insights/Maturing-Product-Portfolio.htm.
- CASKEY, Thomas C.:** *The Drug Development Crisis: Efficiency and Safety*, 58 Annual Review of Medicine 1 (2007).
- CHANDON, Pierre:** *Innovative Marketing Strategies after Patent Expiry: The Case of GSK's Antibiotic Clamoxyl in France*, 4 International Journal of Medical Marketing 65 (2004).

- DIMASI, Joseph A./ GRABOWSKI, Henry G.:** *The Cost of Biopharmaceutical R&D: Is Biotech Different?*, 28 *Managerial and Decision Economics* 469 (2007).
- DREXL, Josef:** *Responding to the Challenges for Development with a Competition-Oriented Approach*, in 1 *International Centre for Trade and Sustainable Development, Views on the Future of the Intellectual Property System* 17 (John H. Barton et al. eds., 2007).
- DREXL, Josef:** *Deceptive Conduct in the Patent World – A Case for US Antitrust and EU Competition Law?*, in *Patents and Technological Progress in a Globalized World – Liber Amicorum Joseph Straus* 137 (Wolrad Prinz zu Waldeck und Pymont et. al. eds., 2009).
- DREXL, Josef:** *Pay-for-Delay – Zur kartellrechtlichen Beurteilung streitbeilegender Vereinbarungen bei Pharma-Patenten*, in *Sektoruntersuchung Pharma der Europäischen Kommission – Kartellrechtliche Disziplinierung des Patentsystems?* 13 (Bardehle, Pagenberg, Dost Altenburg, Geissele eds., Carl Heymanns Verlag 2010).
- ECCLES, Richard:** *EU: European Commission Reports on the Monitoring of Patent Settlement Agreements* (Online News Update, Bird & Bird, Jul. 28, 2010).
- ECCLES, Richard:** *EU: European General Court upholds findings of abuse of dominant position by AstraZeneca for misusing the SPC and marketing authorising systems* (Online News Update, Bird & Bird, Jul. 28, 2010).
- ETRO, Federico:** *Competition, Innovation, and Antitrust, A Theory of Market Leaders and Its Policy Implications* (Pringer-Verlag 2007).
- FACKELMANN, Christian R.:** *Patentschutz und ergänzende Schutzinstrumente für Arzneimittel im Spannungsfeld von Wettbewerb und Innovation* (Josef Drexel et al. eds., Carl Heymanns Verlag 2009).
- FINES, Frank L.:** *The EC Competition Law on Technology Licensing* (Sweet&Maxwell 2006).
- FRANK, Richard G.:** *Behavioral Economics and Health Economics* (Yrjo Jahns-son Foundation, 50th Anniversary Conference on Economic Institutions and Behavioral Economics, May 20, 2004).
- GASSNER, Ulrich:** *Markteintrittsrelevante Vereinbarungen zwischen Original- und Generikaherstellern im Kreuzfeuer*, 1 *Arzneimittel & Recht* 3 (2010).
- GOODALL, Simon et al.:** *Capitalizing on the Crisis – New Ways to Create Value in Biopharma*, BCG Focus (The Boston Consulting Group 2009).

- GROGAN, Kevin:** *Servier could be hit with hefty fine for 'misleading' EU* (PharmaTimes Online Jul. 28, 2010), available at, http://www.pharmatimes.com/Article/10-0728/Servier_could_be_hit_with_hefty_fine_for_misleading_EU.aspx.
- HARACOGLU, Irina:** *Competition Law and Patents – A Follow-on Innovation Perspective in the Biopharmaceutical Industry* (Steven D. Anderman et al. eds., Edward Elgar Publishing 2008).
- HARHOFF, Dietmar et al.:** *The strategic use of patents and its implications for enterprise and competition policies* (final report, Tender for No. ENTR/05/82, Jul. 8 2007).
- JONES, Alison/ SUFRIN, Brenda:** *EC Competition Law Text, Cases, and Materials*, (3rd ed. Oxford University Press 2008).
- LANDES, William M./ POSNER, Richard A.:** *The Economic Structure of Intellectual Property Law* (The Belknap Press of Harvard University Press 2003).
- LAWRANCE, Sophie/ BRISTOWS, Pat Treacy:** *The Commission's AstraZeneca decision: delaying generic entry is an abuse of a dominant position*, 1 *Journal of Intellectual Property Law & Practice* 7 (2005).
- LEMLEY, Mark/ SHAPIRO, Carl:** *Probabilistic Patents*, 19 *The Journal of Economic Perspectives* 75 (2005).
- MÜLLER, Michael C. et al.:** *Die Bedeutung der Generikaindustrie für die Gesundheitsversorgung in Deutschland* (Accenture Management Consulting 2005), available at http://www.accenture.com/Countries/Germany/Research_and_Insights/Generikaindustrie.htm.
- OHLY, Ansgar:** *Geistiges Eigentum und Wettbewerbsrecht – Konflikt oder Symbiose*, in *Geistiges Eigentum und Gemeinfreiheit* 47 (Ansgar Ohly and Diethelm Kippel eds., 2007).
- OUTTERSON, Kevin:** *Counterfeit drugs: the good, the bad and the ugly*, 16 *Albany Law Journal of Science & Technology* 526 (2006).
- PORSTNER, Thomas:** *Patienten müssen am ersten Tag nach Ablauf des Patents sofortigen Zugang zu bezahlbarer generischer Medizin erhalten*, in *Sektoruntersuchung Pharma der Europäischen Kommission – Kartellrechtliche Disziplinierung des Patentsystems?* 3 (Bardehle, Pagenberg, Dost Altenburg, Geisele eds., Carl Heymanns Verlag 2010).
- PRIDDIS, Simon/ CONSTANTINE, Simon:** *The Findings and Wider Impact of the EU Pharmaceutical Sector Inquiry*, 24 *Antitrust* 29 (2010).

- RAB, Suzanne/ HEENAN, Bróna:** *European Commission Launches Monitoring of Patent Settlement Agreements*, 15 *Hogan & Hartson Life Sciences Competition & Antitrust Update* 12 (2010).
- RAB, Suzanne/ MONNOYEUR, Daphne:** *European Commission Inspections in the Pharmaceutical Sector – Antitrust Scrutiny Continues*, 14 *Hogan & Hartson Life Sciences Competition & Antitrust Update* 10 (2009).
- ROSENBERG, David:** *A view of the research-based industry, in Sektoruntersuchung Pharma der Europäischen Kommission – Kartellrechtliche Disziplinierung des Patentsystems?* 51 (Bardehle, Pagenberg, Dost Altenburg, Geissele eds., Carl Heymanns Verlag 2010).
- ROSS, Stephen A. et al.:** *Corporate Finance* (6th int. ed., McGraw-Hill Higher Education 2002) (1988).
- SCHMIDTCHEN, Dieter:** *Der „more economic approach“ in der europäischen Wettbewerbspolitik – Ein Konzept mit Zukunft, in Internationalisierung des Rechts und seine ökonomische Analyse* 473 (Thomas Eger et al. eds., 2008).
- SCHNEIDER, Udo:** *Kostenfalle Gesundheitswesen? Ökonomische Herausforderung und Perspektiven der Gesundheitssicherung* (University of Bayreuth, Discussion Paper No. 08-03, 2003).
- SCHNELLE, Ulrich:** *Missbrauch einer marktbeherrschenden Stellung durch Patentanmeldungs- und –verwaltungsstrategien*, 8 *Gewerblicher Rechtsschutz und Urheberrecht Praxis im Immaterialgüter und Wettbewerbsrecht* 169 (2010).
- SCHNICHELS, Dominik:** *The Application of European Competition Law to the Pharmaceutical Sector – Some Personal Thoughts* (Fordham Annual Conference on International Antitrust Law and Policy, discussion paper, Sept. 2009).
- SHAPIRO, Carl:** *Antitrust Limits to Patent Settlements*, 34 *RAND Journal of Economics* 391 (2003).
- STAUDER, Dieter/ BÖHNER, Pascal:** *Bericht über die Diskussion, in Sektoruntersuchung Pharma der Europäischen Kommission – Kartellrechtliche Disziplinierung des Patentsystems?* 73 (Bardehle Pagenberg Dost Altenburg Geissler eds., 2010).
- STOCK, Eric J.:** *Patent Settlement Developments: California Court Dismisses Challenge to Patent Settlement as Legislation Moves Forward in Congress*, 14 *Hogan & Hartson Life Sciences Competition & Antitrust Update* 2 (2009).
- STRAUS, Joseph,** *Patentanmeldung als Missbrauch der marktbeherrschenden Stellung nach Art. 82 EGV?*, 2 *Gewerblicher Rechtsschutz und Urheberrecht Internationaler Teil* 93 (2009).

SULE, Satish/ SCHNICHEL, Dominik: *Die Untersuchung des pharmazeutischen Wirtschaftszweigs durch die Kommission*, 20 Europäische Zeitschrift für Wirtschaftsrecht 129 (2009).

TURNER, Neil: *Containing global pharmaceutical costs: supply versus demand*, The Pharma Letter (Oct. 20, 2000) available at <http://www.thepharmaletter.com/file/37084/containing-global-pharmaceutical-costs-supply-versus-demand-by-neil-turner.html>.

ULLRICH, Hanns: *Wahrung von Wettbewerbsfreiräumen innerhalb der Schutzrechtsverwertung – Die Regelung des Innovationswettbewerbs im und durch das Patentrecht*, in Sektoruntersuchung Pharma der Europäischen Kommission – Kartellrechtliche Disziplinierung des Patentsystems? 29 (Bardehle, Pagenberg, Dost Altenburg, Geissele eds., Carl Heymanns Verlag 2010).

ULLRICH, Hanns/ HEINEMANN, Andreas, in *Wettbewerbsrecht EC Vol. 1 Part 2*, 162 (Ulrich Immenga and Ernst-Joachim Mestmäcker eds. 2007).

WALSH, John P. et al.: *Research Tool Patenting and Licensing and Biomedical Innovation*, in *Patents in the Knowledge-Based Society* 285 (Wesley M. Cohen and Stephen A. Merrill eds., National Academic Press 2003).

Reports, Press Releases and Proposed Legislation

Commission Communication, Executive Summary of the Pharmaceutical Sector Inquiry Report (Jul. 8, 2009).

Commission of the European Communities, Safe, Innovative and Accessible Medicines: a Renewed Vision for the Pharmaceutical Sector, COM (2008) 666 final (Dec. 10, 2008).

EU Commission, Competition DG, Pharmaceutical Sector Inquiry Final Report (Jul 8, 2009), available at <http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html>.

EU Commission, Competition DG, Guidance on the Commission's Enforcement Priorities in Applying Article 82 of the EC Treaty to Abusive Exclusionary Conduct by Dominant Undertakings, 2009 O.J. (C45) 7.

European Federation of Pharmaceutical Industries and Associations (EFPIA), The Pharmaceutical Industry in Figures (2009).

GIURI, Paola et al.: Inventors and invention processes in Europe: Results from the PatVal-EU survey, 36(8) Research Policy Elsevier 1107 (2007).

PharmExec Staff, The PharmExec 50, 5 Pharmaceutical Executive 68 (2009).

- Press Release IP/04/382**, European Commission, Commission concludes on Microsoft investigation, imposes conduct remedies and a fine (Mar 24, 2004).
- Press Release IP/10/08**, European Commission, Antitrust: Commission opens formal proceedings against pharmaceutical company Lundbeck (Jan. 7, 2010).
- Press Release IP/10/12**, European Commission, Antitrust: Commission launches monitoring of patent settlements concluded between pharmaceutical companies (Jan. 12, 2010).
- Press Release IP/10/887**, European Commission, Antitrust: Commission welcomes decrease of potentially problematic patent settlements in EU pharma sector (Jul. 5, 2010).
- Press Release MEMO/08/20**, European Commission, Antitrust – sector inquiry into pharmaceuticals – frequently asked questions (Jan 1, 2008).
- Press Release MEMO/09/321**, European Commission, Antitrust: shortcomings in pharmaceutical sector require further action – frequently asked questions, (Jul 8, 2009).
- Press Release MEMO/09/322**, European Commission, Antitrust: Commission opens formal proceedings against Les Laboratoires Servier and a number of generic pharmaceutical companies (Jul. 8, 2009).
- RAESIDE, Anthony et al.**, World Preview 2016, EvaluatePharma Report 3 (May 2010).

Speeches and Addresses

- DESHEH, Eyal, Chief Financial Officer, Teva Pharmaceuticals/ MARTH, Bill, President and Chief Executive Officer, Teva North America, Presentation at the 27th annual JP Morgan Healthcare Conference: *Introducing the World Leader in Generic Pharmaceuticals* (Jan. 12, 2009).
- HARHOFF, Dietmar, Head of Institut für Innovationsforschung, Technologiemanagement und Entrepreneurship, Ludwig-Maximilians-Universität Munich, speech at the anniversary event '30 Jahre Monopolkommission': *Innovationen und Wettbewerbspolitik – Ansätze zur ökonomischen Analyse des Patentsystems* (Nov. 5, 2004).

LEIBOWITZ, Jon, Chairman, U. S. Federal Trade Commission, speech at the Center for American Progress: *'Pay-for-delay' Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, and Help Pay for health Care Reform (The \$35 billion solution)* (Jun. 23, 2009) (available at <http://www.ftc.gov/speeches/leibowitz/090623payfordelayspeech.pdf>)

RUMMELT, Andreas, Chief Executive Officer, Sandoz, Presentation at the Merrill Lynch Generics Conference: *Expanding the Boundaries of Generics* (Dec. 1, 2008).

SPEK, Hanspeter, Executive Vice President Pharmaceutical Operations, Sanofi-Aventis, Presentation at the Pharmaceuticals Emerging Markets Conference (May 6, 2009).

ULLRICH, Hanns, Professor emeritus, Max-Planck-Institute, speech at the MIPLC Trilateral Patent Law Conference (May 14, 2010).

Statues

Council Directive 2001/83, 2001 O.J. (L 311) 67 (EC) (Community Code relating to medicinal products for human use).

Council Directive 2004/27, 2004 O.J. (L 136) 34 (EC) (Introduction of the 'Bolar Exemption', i.e. amendment to Council Directive 2001/83 on the Community Code relating to medicinal products for human use).

Council Regulation 141/2000, 2000 O. J. (L 18) 1 (EC) (Orphan medicinal products).

Council Regulation 1/2003, 2003 O.J. (L 1) (Modernization Regulation).

Council Regulation 1383/2003, 2003 O. J. (L 196) (Customs actions against goods suspected of infringing IP Rights and the measures to be taken against goods found to have infringed such rights).

Commission Regulation 772/2004, 2004 O. J. (L 123) (EC) (Application of Art. 81(3) EC Treaty to technology transfer agreements).

Council Regulation 1901/2006, 2006 O. J. (L 378) 1 (EC) (Medicinal Products for paediatric use).

Council Regulation 469/2009, 2009 O.J. (L 152) (Supplementary Protection Certificates for Medicinal Products).

Case Law

- Case 85/76**, Hoffmann-La Roche & Co. AG v. Comm'n, 1979
E.C.R. 00461.
- Case C-241/91 and C-242/91**, Radio Telefis Eireann (RTE) and Independent
Relevision Publications (ITP) v Comm'n, 1995
E.C.R. I-743.
- Case 56/64 and 58/64**, Etablissements Consten SA and Grundig-Verkaufs-GmbH
v Comm'n, 1996 E.C.R. 299.
- Case C-333/94 P**, Tetra Pak International SA v. Comm'n, 1996
E.C.R. I-05951.
- Case T-111/96**, ITT Promedia NV v Commission, 1998 E.C.R. II-2937
- Case C-7/97**, Oscar Bronner, 1998 E.C.R. I-7791.
- Case T-62/98**, Volkswagen AG v. Comm'n, 2000 E.C.R. II-2707.
- Commission Decision, Case IV/36.888**, 1998 World Cup, 2000
O.J. (L 5).
- Case T-203/01**, Manufacture française des pneumatiques Michelin v Commission,
2003 E.C.R. II-4071.
- In re Ciprofloxacin Hydrochloride Antitrust Litigation** 363 F. Supp. 2d 514
(E.D.N.Y. 2005) and 261 F. Supp. 2d 188 (E.D.N.Y. 2003).
- Case C-418/01**, IMS Health GmbH & Co. OHG v. NDC Health GmbH & Co. KG,
2004 E.C.R. I-05039.
- Case A363**, Glaxo v. Principi Attivi, 2006, decision of Autorità Garante della
Concorrenza e del Mercato.
- Joint Cases C-501/06 P, C-513/06 P, C-515/06 P and C-519/06 P**, GlaxoSmithK-
line Services Unlimited v. Comm'n (under appeal – not published yet, see Case
T-168/01, GlaxoSmithKlineServices Unlimited v. Comm'n, 2006 E.C.R.
II-2969.
- eBay Inc. and Half.com v. MercExchange L.L.C.**, 74 U.S.L.W. 4248 (2006).
- Case T-201/04**, Microsoft Corp. v. Comm'n, 2007 E.C.R. II-03601.
- Actavis UK Ltd v. Merck & Co Inc**, 2008 EWCA Civ 444,
2008 R.P.C. 26.
- Case C-195/09**, Synthon BV v. Merz Pharma GmbH & Co. KG, 2009 O.J. (C 193)
(pending case as of reference for preliminary ruling from High Court of Justice,
England and Wales).

Case T-321/05, AstraZeneca AB and AstraZeneca plc v. Comm'n, 2010 ECJ CELEX LEXIS 62005A0321 (July 1, 2010).

Case COMP/B2/39246, Boehringer Ingelheim v. Comm'n, 2007 (not yet published).